Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06382142 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)

StatusActive, Not Recruiting
PhasePhase 3
Started2024-06-21
View on ClinicalTrials.gov ↗

Amendment history

2026-07-22
Study Status v7
Primary completion moved earlier: 2026-06 → 2026-01-13
Completion pushed: 2026-06 → 2027-12
2026-04-15
Study Identification, Study Status v6
Study title+16 characters
[...] Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)
2025-11-13
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v5
Trial statusRecruiting→Active, Not Recruiting
Enrollment targetestimated 406→confirmed 418
Study sitesdetails revised at 1 of 1 site
2025-04-30
Study Status, Arms and Interventions v4
Re-verified, no change to tracked fields
2024-09-24
Study Status, Study Design, Outcome Measures v3
Enrollment target436→406
Secondary endpoints6 to 5 entries
Overall survival (OS)
Primary endpoints1 to 2 entries
Overall survival (OS)
Show 2 earlier versions
2024-07-02
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2026-05→2026-06
Completion date2026-05→2026-06
Start dateestimated 2024-05→confirmed 2024-06-21
Study sitesdetails revised at 1 of 1 site
2024-05-11
Study Status v1
Re-verified, no change to tracked fields
2024-04-19
Original filing
This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced or metastatic Triple-Negative breast cancer after taxane failure.
Trial Details
NCT Number NCT06382142
Lead Sponsor Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Conditions Triple-Negative Breast Cancer
Enrollment 418 participants
Start Date 2024-06-21
Primary Completion 2026-01-13 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-23